{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T03:16:03Z","timestamp":1791083763973,"version":"4.1.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,1,23]],"date-time":"2018-01-23T00:00:00Z","timestamp":1516665600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016285","name":"TDR","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016285","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000278","name":"Department for International Development, UK Government","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000278","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007660","name":"Universiteit Antwerpen","doi-asserted-by":"publisher","award":["TT-ZAPBOF 33049"],"award-info":[{"award-number":["TT-ZAPBOF 33049"]}],"id":[{"id":"10.13039\/501100007660","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013996","name":"Global Health Innovative Technology Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013996","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004423","name":"World Health Organization","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004423","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal for Parasitology: Drugs and Drug Resistance"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1016\/j.ijpddr.2018.01.006","type":"journal-article","created":{"date-parts":[[2018,1,31]],"date-time":"2018-01-31T13:42:00Z","timestamp":1517406120000},"page":"81-86","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":46,"title":["In vitro and in vivo pharmacodynamics of three novel antileishmanial lead series"],"prefix":"10.1016","volume":"8","author":[{"given":"M.","family":"Van den Kerkhof","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3530-0567","authenticated-orcid":false,"given":"D.","family":"Mabille","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Chatelain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3538-8116","authenticated-orcid":false,"given":"C.E.","family":"Mowbray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Braillard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Hendrickx","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Maes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4870-3202","authenticated-orcid":false,"given":"G.","family":"Caljon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijpddr.2018.01.006_bib1","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0001870","article-title":"Fexinidazole: a potential new drug candidate for Chagas disease","volume":"6","author":"Bahia","year":"2012","journal-title":"PLoS Neglected Trop. Dis."},{"key":"10.1016\/j.ijpddr.2018.01.006_bib2","first-page":"175","article-title":"Drug discovery and development for neglected diseases: the DNDi model","volume":"5","author":"Chatelain","year":"2011","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.ijpddr.2018.01.006_bib3","doi-asserted-by":"crossref","first-page":"704","DOI":"10.3201\/eid1804.110841","article-title":"Leishmania resistance to miltefosine associated with genetic marker","volume":"18","author":"Cojean","year":"2012","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/j.ijpddr.2018.01.006_bib4","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1111\/j.1469-0691.2011.03630.x","article-title":"Leishmaniasis chemotherapy\u2013challenges and opportunities","volume":"17","author":"Croft","year":"2011","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.ijpddr.2018.01.006_bib5","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1128\/CMR.19.1.111-126.2006","article-title":"Drug resistance in leishmaniasis","volume":"19","author":"Croft","year":"2006","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.ijpddr.2018.01.006_bib6","doi-asserted-by":"crossref","first-page":"319","DOI":"10.2174\/1381612023396258","article-title":"Chemotherapy of leishmaniasis","volume":"8","author":"Croft","year":"2002","journal-title":"Curr. Pharmaceut. Des."},{"key":"10.1016\/j.ijpddr.2018.01.006_bib7","doi-asserted-by":"crossref","first-page":"815023","DOI":"10.1155\/2015\/815023","article-title":"Advances in development of new treatment for leishmaniasis","volume":"2015","author":"de Menezes","year":"2015","journal-title":"BioMed Res. Int."},{"key":"10.1016\/j.ijpddr.2018.01.006_bib8","doi-asserted-by":"crossref","first-page":"e1932","DOI":"10.1371\/journal.pntd.0001932","article-title":"A static-cidal assay for Trypanosoma brucei to aid hit prioritisation for progression into drug discovery programmes","volume":"6","author":"De Rycker","year":"2012","journal-title":"PLoS Neglected Trop. Dis."},{"key":"10.1016\/j.ijpddr.2018.01.006_bib9","doi-asserted-by":"crossref","first-page":"2707","DOI":"10.1093\/jac\/dks273","article-title":"Efficacy and tolerability of oleylphosphocholine (OlPC) in a laboratory model of visceral leishmaniasis","volume":"67","author":"Fortin","year":"2012","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.ijpddr.2018.01.006_bib10","article-title":"A method for screening compounds against visceral leishmaniasis in the hamster","volume":"42","author":"Franchino","year":"1956","journal-title":"J. Parasitol."},{"key":"10.1016\/j.ijpddr.2018.01.006_bib11","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ijpddr.2012.01.003","article-title":"Visceral leishmaniasis treatment: what do we have, what do we need and how to deliver it?","volume":"2","author":"Freitas-Junior","year":"2012","journal-title":"Int. J. Parasitol Drugs Drug Resist."},{"key":"10.1016\/j.ijpddr.2018.01.006_bib12","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1093\/jac\/dku422","article-title":"Nitroimidazo-oxazole compound DNDI-VL-2098: an orally effective preclinical drug candidate for the treatment of visceral leishmaniasis","volume":"70","author":"Gupta","year":"2015","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.ijpddr.2018.01.006_bib13","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1517\/14656566.7.7.953","article-title":"Nitazoxanide, a broad-spectrum thiazolide anti-infective agent for the treatment of gastrointestinal infections","volume":"7","author":"Hemphill","year":"2006","journal-title":"Expet Opin. Pharmacother."},{"key":"10.1016\/j.ijpddr.2018.01.006_bib14","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1007\/s00436-014-3835-7","article-title":"Experimental selection of paromomycin and miltefosine resistance in intracellular amastigotes of Leishmania donovani and L. infantum","volume":"113","author":"Hendrickx","year":"2014","journal-title":"Parasitol. Res."},{"key":"10.1016\/j.ijpddr.2018.01.006_bib15","doi-asserted-by":"crossref","first-page":"3023","DOI":"10.1093\/jac\/dkv237","article-title":"Lack of correlation between the promastigote back-transformation assay and miltefosine treatment outcome","volume":"70","author":"Hendrickx","year":"2015","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.ijpddr.2018.01.006_bib16","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0005620","article-title":"Combined treatment of miltefosine and paromomycin delays the onset of experimental drug resistance in Leishmania infantum","volume":"11","author":"Hendrickx","year":"2017","journal-title":"PLoS Neglected Trop. Dis."},{"key":"10.1016\/j.ijpddr.2018.01.006_bib17","doi-asserted-by":"crossref","first-page":"e1151","DOI":"10.1371\/journal.pntd.0001151","article-title":"SCYX-7158, an orally-active benzoxaborole for the treatment of stage 2 human African trypanosomiasis","volume":"5","author":"Jacobs","year":"2011","journal-title":"PLoS Neglected Trop. Dis."},{"key":"10.1016\/j.ijpddr.2018.01.006_bib18","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.molbiopara.2008.12.007","article-title":"Paromomycin: uptake and resistance in Leishmania donovani","volume":"164","author":"Jhingran","year":"2009","journal-title":"Mol. Biochem. Parasitol."},{"key":"10.1016\/j.ijpddr.2018.01.006_bib19","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1093\/jac\/dkw409","article-title":"In vitro 'time-to-kill' assay to assess the cidal activity dynamics of current reference drugs against Leishmania donovani and Leishmania infantum","volume":"72","author":"Maes","year":"2017","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.ijpddr.2018.01.006_bib20","article-title":"Basic microbiological techniques used in antibacterial drug discovery","author":"Motyl","year":"2006","journal-title":"Curr. Protoc. Pharmacol."},{"key":"10.1016\/j.ijpddr.2018.01.006_bib21","series-title":"Anti-leishmanial Drug Discovery: Past, Present and Future Perspectives","first-page":"24","article-title":"Drug discovery for leishmaniasis","author":"Mowbray","year":"2017"},{"key":"10.1016\/j.ijpddr.2018.01.006_bib22","doi-asserted-by":"crossref","first-page":"9615","DOI":"10.1021\/acs.jmedchem.5b01456","article-title":"Novel amino-pyrazole Ureas with potent in vitro and in vivo antileishmanial activity","volume":"58","author":"Mowbray","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ijpddr.2018.01.006_bib23","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.ejps.2014.09.006","article-title":"In vitro metabolism, disposition, preclinical pharmacokinetics and prediction of human pharmacokinetics of DNDI-VL-2098, a potential oral treatment for Visceral Leishmaniasis","volume":"65","author":"Mukkavilli","year":"2014","journal-title":"Eur. J. Pharmaceut. Sci."},{"key":"10.1016\/j.ijpddr.2018.01.006_bib24","doi-asserted-by":"crossref","first-page":"4379","DOI":"10.1128\/AAC.00498-10","article-title":"Discovery of novel orally bioavailable oxaborole 6-carboxamides that demonstrate cure in a murine model of late-stage central nervous system african trypanosomiasis","volume":"54","author":"Nare","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ijpddr.2018.01.006_bib25","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.pt.2014.04.003","article-title":"Nitro drugs for the treatment of trypanosomatid diseases: past, present, and future prospects","volume":"30","author":"Patterson","year":"2014","journal-title":"Trends Parasitol."},{"key":"10.1016\/j.ijpddr.2018.01.006_bib26","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.exppara.2016.01.007","article-title":"Effects of nitro-heterocyclic derivatives against Leishmania (Leishmania) infantum promastigotes and intracellular amastigotes","volume":"163","author":"Petri e Silva","year":"2016","journal-title":"Exp. Parasitol."},{"key":"10.1016\/j.ijpddr.2018.01.006_bib27","doi-asserted-by":"crossref","first-page":"3367","DOI":"10.1021\/jm031145u","article-title":"3-Aminopyrazole inhibitors of CDK2\/cyclin A as antitumor agents. 1. Lead finding","volume":"47","author":"Pevarello","year":"2004","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ijpddr.2018.01.006_bib28","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0140-6736(09)61117-X","article-title":"Nifurtimox-eflornithine combination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis: a multicentre, randomised, phase III, non-inferiority trial","volume":"374","author":"Priotto","year":"2009","journal-title":"Lancet"},{"issue":"Suppl. 1","key":"10.1016\/j.ijpddr.2018.01.006_bib29","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1007\/s00436-002-0754-9","article-title":"Nitroheterocyclic drugs with broad spectrum activity","volume":"90","author":"Raether","year":"2003","journal-title":"Parasitol. Res."},{"key":"10.1016\/j.ijpddr.2018.01.006_bib30","doi-asserted-by":"crossref","first-page":"186","DOI":"10.2174\/157489211795328459","article-title":"Synthesis, characterization and in-vitro antiproliferative effects of novel 5-amino pyrazole derivatives against breast cancer cell lines","volume":"6","author":"Raju","year":"2011","journal-title":"Recent Pat. Anti-Cancer Drug Discov."},{"key":"10.1016\/j.ijpddr.2018.01.006_bib31","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1126\/science.1142189","article-title":"An antifungal agent inhibits an aminoacyl-tRNA synthetase by trapping tRNA in the editing site","volume":"316","author":"Rock","year":"2007","journal-title":"Science"},{"key":"10.1016\/j.ijpddr.2018.01.006_bib32","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1086\/425359","article-title":"Oral miltefosine for leishmaniasis in immunocompromised patients: compassionate use in 39 patients with HIV infection","volume":"39","author":"Sindermann","year":"2004","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.ijpddr.2018.01.006_bib33","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s40249-016-0112-2","article-title":"Current challenges in treatment options for visceral leishmaniasis in India: a public health perspective","volume":"5","author":"Singh","year":"2016","journal-title":"Infect. Dis. Poverty"},{"key":"10.1016\/j.ijpddr.2018.01.006_bib34","first-page":"733","article-title":"Miltefosine in the treatment of leishmaniasis: clinical evidence for informed clinical risk management","volume":"3","author":"Sundar","year":"2007","journal-title":"Ther. Clin. Risk Manag."},{"key":"10.1016\/j.ijpddr.2018.01.006_bib35","first-page":"98","article-title":"Recent developments and future prospects in the treatment of visceral leishmaniasis","volume":"3","author":"Sundar","year":"2016","journal-title":"Ther. Adv. Infect. Dis."},{"key":"10.1016\/j.ijpddr.2018.01.006_bib36","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/S0140-6736(10)62050-8","article-title":"Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial","volume":"377","author":"Sundar","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.ijpddr.2018.01.006_bib37","doi-asserted-by":"crossref","first-page":"e525","DOI":"10.1016\/j.ijid.2011.03.021","article-title":"Recent advances in leishmaniasis treatment","volume":"15","author":"Tiuman","year":"2011","journal-title":"Int. J. Infect. Dis."},{"key":"10.1016\/j.ijpddr.2018.01.006_bib38","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1017\/S003118201300098X","article-title":"Pharmacokinetics and pharmacodynamics utilizing unbound target tissue exposure as part of a disposition-based rationale for lead optimization of benzoxaboroles in the treatment of Stage 2 Human African Trypanosomiasis","volume":"141","author":"Wring","year":"2014","journal-title":"Parasitology"},{"key":"10.1016\/j.ijpddr.2018.01.006_bib39","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3003326","article-title":"The anti-trypanosome drug fexinidazole shows potential for treating visceral leishmaniasis","volume":"4","author":"Wyllie","year":"2012","journal-title":"Sci. Transl. Med."}],"container-title":["International Journal for Parasitology: Drugs and Drug Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211320717301598?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211320717301598?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T14:49:26Z","timestamp":1761922166000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211320717301598"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["S2211320717301598"],"URL":"https:\/\/doi.org\/10.1016\/j.ijpddr.2018.01.006","relation":{},"ISSN":["2211-3207"],"issn-type":[{"value":"2211-3207","type":"print"}],"subject":[],"published":{"date-parts":[[2018,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In vitro and in vivo pharmacodynamics of three novel antileishmanial lead series","name":"articletitle","label":"Article Title"},{"value":"International Journal for Parasitology: Drugs and Drug Resistance","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijpddr.2018.01.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier Ltd on behalf of Australian Society for Parasitology.","name":"copyright","label":"Copyright"}]}}